Mainstays of biomedical research, permanent lines of cloned cells are used to study the biology of health and disease and to test prospective medical therapies. Yet, all too often, these apparent pillars of bioscience and biotechnology crumble because they are crafted from faulty starting materials: misidentified or cross-contaminated cell lines. Writing in the June 2016 issue of PLOS Biology, scientists from the National Institute of Standards and Technology (NIST) call for "community action" to assemble a "comprehensive toolkit for assuring the quality of cell lines," employed at the start of every study.
cancer
See the following -
More Data, Better Drugs: Genetech, PatientsLikeMe Ink Groundbreaking Research Pact
Ron Leuty | BiotechSF - San Francisco Business Times | April 7, 2014
Genentech Inc. will mine the deep online patient network of PatientsLikeMe to pinpoint ways of using patients' real experience with diseases and drugs for better research. The five-year agreement is the first broad research collaboration between Cambridge, Mass.-based PatientsLikeMe and a drug company, but it also demonstrates how open-source research and social media are increasingly tapped by companies to get real-world insights into diseases and how patients respond to treatments.
- Login to post comments
More Money Won’t Win The War On Cancer
Jacoba Urist | The Atlantic | August 28, 2013
A broken grant structure, turf wars, and an exodus of scientists for other professions are bigger barriers to progress than a lack of funding. Read More »
- Login to post comments
NCI Plans Database Of Patients Who Experience Miraculous Recoveries
Nick Paul Taylor | Fierce Biotech IT | April 14, 2014
Every clinical trial has its outliers. Some patients respond far better to the treatment than the rest, but the focus on efficacy across the study population means these results--and their implications--are lost in the shuffle.
- Login to post comments
New Antibiotic Alternative Traps and Eats Bacterial Toxins
BEC Crew | Science Alert | November 6, 2014
Researches in Switzerland have come up with what could be a viable alternative to antibiotics - cell structures called liposomes that can bait, trap and neutralise deadly bacterial toxins. As much trouble as we seem to be in right now due to the creeping issue of antibiotic resistance, imagine what the world would've looked like if the first antibiotic - penicillin - wasn’t discovered almost 90 years ago. We owe a great deal to this fungi-derived wonder-drug, but our absolute reliance on it has now put us at risk...
- Login to post comments
New Biotech Site Sparks Hope For Cancer Treatments
Staff Writer | The Regional News | October 23, 2013
The latest victory in the Myriad Genetics case in Australia, allowing Myriad Genetics to patent isolated DNA, has sparked new debate over the development of new drugs to treat cancer... Read More »
- Login to post comments
New Cancer Cases Worldwide Expected To Skyrocket
Nanci Hellmich | USA Today | February 4, 2014
Cancer deaths worldwide are predicted to rise from 8.2 million annually to 13 million a year with two decades, according to a new report. Read More »
- Login to post comments
New Light-Activated Nanoparticles Kill Over 90% of Antibiotic-Resistant Bacteria
Peter Dockrill | Science Alert | January 19, 2016
Bacterial resistance to antibiotics is a growing problem around the world, responsible for some 2 million infections in the US each year that lead to approximately 23,000 deaths. But a new nanoparticle treatment developed by researchers at the University of Colorado Boulder could provide an effective means of fighting antibiotic-resistant bacteria including Salmonella, E. Coli, and Staphylococcus, based on results in a laboratory environment. In testing with a lab-grown culture, the nanoparticles killed 92 percent of drug-resistant bacterial cells while leaving the other cells intact...
- Login to post comments
NHS Cancer Diagnostic Pathology Thriving In Open Source
Adrian Bridgwater | Open Source Insider | June 4, 2013
Many cancer laboratories in the UK are using antiquated reporting software. Read More »
- Login to post comments
NIST Issues Call For Developing -- And Using -- Consensus Standards To Ensure The Quality Of Cell Lines
Press Release |
National Institute Of Standards And Technology (NIST) |
June 14, 2016
- Login to post comments
OHSU, Intel Partner On Genetics
Bernie Monegain | Healthcare IT News | April 22, 2013
Oregon Health & Science University and Intel Corp. are teaming up to develop next-generation computing technologies that advance the field of personalized medicine by dramatically increasing the speed, precision and cost-effectiveness of analyzing a patient's individual genetic profile. Read More »
- Login to post comments
Oncologists Call For Single Payer In Leading Cancer Journal
Staff Writer | Physicians for a National Health Program (PNHP) | January 17, 2014
A feature article published today in the Journal of Oncology Practice contains an evidence-based appeal by two oncologists, including a past president of the American Society of Clinical Oncology (ASCO), for their colleagues to endorse a single-payer health system. Read More »
- Login to post comments
Open Access And Scientific Breakthroughs
Kamil | Open Science | December 7, 2012
A few days ago, The Chronicle of Higher Education published an article by Peter Suber and Darius Cuplinskas, daringly entitled “Open Access to Scientific Research Can Save Lives”. It relates the case of 15 year-old Jack Andraka, who recently announced he had invented a diagnostic test for pancreatic cancer. Read More »
- Login to post comments
Open Access Empowers 16-Year-Old Jack Andraka To Create Breakthrough Cancer Diagnostic
Staff Writer | Right to Research Coalition | June 11, 2013
Open Access Empowers 16-year-old to Create Breakthrough Cancer Diagnostic: An Interview with Jack Andraka and Dr. Francis Collins, Director of the National Institutes of Health Read More »
- Login to post comments
Open Access Empowers 16-Year-Old Jack Andraka To Create Breakthrough Cancer Diagnostic
Staff Writer | Right to Research Coalition | June 11, 2013
Open Access Empowers 16-year-old to Create Breakthrough Cancer Diagnostic: An Interview with Jack Andraka and Dr. Francis Collins, Director of the National Institutes of Health Read More »
- Login to post comments
Open Access To Genomics May Spur Myeloma Therapy
Ben Guarino | Clinical Oncology | December 1, 2013
The Multiple Myeloma Research Foundation believes a new database—the Researcher Gateway—will revolutionize precision medicine for the disease Read More »
- Login to post comments
Copyright ©2011-2020 Open Health Marketplace, LLC. All Rights Reserved.